FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387581629> ?p ?o ?g. }

• W4387581629 abstract "Abstract Background: This study aimed to evaluate the efficacy and side effects of first-line afatinib treatment in a real-world setting in Vietnam. Methods: This retrospective study was conducted across nine hospitals in Vietnam. Advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients who received afatinib as first-line therapy between April 2018 and June 2022 were included, and patient medical records were reviewed. Key outcomes were overall response rate (ORR), time-to-treatment failure (TTF), and tolerability. Results: A total of 343 patients on first-line afatinib were eligible for the study. EGFR exon 19 deletion (Del19) alone was detected in 46.9% of patients, L858R mutation alone in 26.3%, and other uncommon EGFR mutations, including compound mutations, in 26.8%. Patients with brain metastases at baseline were 25.4%. Patients who received 40 mg, 30 mg, and 20 mg as starting doses of afatinib were 58.6%, 39.9%, and 1.5%, respectively. The ORR was 78.1% in the overall population, 82.6% in the Del19 mutation subgroup, 73.3% in the L858R mutation subgroup, and 75.0% in the uncommon mutation subgroup ( p >0.05). The univariate and multivariate analyses indicate that the ORR increased when the starting dose was 40 mg compared to starting doses below 40 mg (83.9% vs 74.3%, p =0.034). The median TTF (mTTF) was 16.7 months (CI 95%: 14.8 – 18.5) in all patients, with a median follow-up time of 26.2 months. The mTTF was longer in patientsin the common EGFR mutation subgroup (Del19/L858R) than in those in the uncommon mutation subgroup (17.5 vs 13.8 months, p =0.045) and in those without versus with brain metastases at baseline (17.5 vs 15.1 months, p =0.049). There were no significant differences in the mTTF between subgroups based on the starting dose of 40 mg and <40 mg (16.7 vs 16.9 months, p >0.05). The most common treatment-related adverse events (any grade/grade ≥3) were diarrhea (55.4%/3.5%), rash (51.9%/3.2%), paronychia (35.3%/5.0%), and stomatitis (22.2%/1.2%). Conclusions: Afatinib demonstrated clinical effectiveness and good tolerability in Vietnamese EGFR-mutant NSCLC patients. In our real-world setting, administering a starting dose below 40 mg might result in a reduction in ORR; however, it might not have a significant impact on TTF." @default.
• W4387581629 created "2023-10-13" @default.
• W4387581629 creator A5003596801 @default.
• W4387581629 creator A5005906180 @default.
• W4387581629 creator A5016986363 @default.
• W4387581629 creator A5021057022 @default.
• W4387581629 creator A5034120348 @default.
• W4387581629 creator A5037592775 @default.
• W4387581629 creator A5038274711 @default.
• W4387581629 creator A5039554820 @default.
• W4387581629 creator A5040245741 @default.
• W4387581629 creator A5055341612 @default.
• W4387581629 creator A5063732406 @default.
• W4387581629 creator A5064381851 @default.
• W4387581629 creator A5071803804 @default.
• W4387581629 creator A5074538797 @default.
• W4387581629 creator A5075622668 @default.
• W4387581629 creator A5075849754 @default.
• W4387581629 creator A5075862299 @default.
• W4387581629 creator A5076611368 @default.
• W4387581629 creator A5076713972 @default.
• W4387581629 creator A5082591630 @default.
• W4387581629 creator A5086624112 @default.
• W4387581629 creator A5088212631 @default.
• W4387581629 creator A5093052223 @default.
• W4387581629 date "2023-10-12" @default.
• W4387581629 modified "2023-10-14" @default.
• W4387581629 title "A Real-World Cohort Study of First-Line Afatinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer in Vietnam" @default.
• W4387581629 cites W2040299716 @default.
• W4387581629 cites W2096198395 @default.
• W4387581629 cites W2339311613 @default.
• W4387581629 cites W2732003254 @default.
• W4387581629 cites W2738531764 @default.
• W4387581629 cites W2772893696 @default.
• W4387581629 cites W2783592110 @default.
• W4387581629 cites W2793959215 @default.
• W4387581629 cites W2808643725 @default.
• W4387581629 cites W2962757024 @default.
• W4387581629 cites W3006608335 @default.
• W4387581629 cites W3086847943 @default.
• W4387581629 cites W3162576579 @default.
• W4387581629 cites W3164128502 @default.
• W4387581629 cites W3196200455 @default.
• W4387581629 cites W4205246856 @default.
• W4387581629 cites W4285553928 @default.
• W4387581629 doi "https://doi.org/10.21203/rs.3.rs-3399075/v1" @default.
• W4387581629 hasPublicationYear "2023" @default.
• W4387581629 type Work @default.
• W4387581629 citedByCount "0" @default.
• W4387581629 crossrefType "posted-content" @default.
• W4387581629 hasAuthorship W4387581629A5003596801 @default.
• W4387581629 hasAuthorship W4387581629A5005906180 @default.
• W4387581629 hasAuthorship W4387581629A5016986363 @default.
• W4387581629 hasAuthorship W4387581629A5021057022 @default.
• W4387581629 hasAuthorship W4387581629A5034120348 @default.
• W4387581629 hasAuthorship W4387581629A5037592775 @default.
• W4387581629 hasAuthorship W4387581629A5038274711 @default.
• W4387581629 hasAuthorship W4387581629A5039554820 @default.
• W4387581629 hasAuthorship W4387581629A5040245741 @default.
• W4387581629 hasAuthorship W4387581629A5055341612 @default.
• W4387581629 hasAuthorship W4387581629A5063732406 @default.
• W4387581629 hasAuthorship W4387581629A5064381851 @default.
• W4387581629 hasAuthorship W4387581629A5071803804 @default.
• W4387581629 hasAuthorship W4387581629A5074538797 @default.
• W4387581629 hasAuthorship W4387581629A5075622668 @default.
• W4387581629 hasAuthorship W4387581629A5075849754 @default.
• W4387581629 hasAuthorship W4387581629A5075862299 @default.
• W4387581629 hasAuthorship W4387581629A5076611368 @default.
• W4387581629 hasAuthorship W4387581629A5076713972 @default.
• W4387581629 hasAuthorship W4387581629A5082591630 @default.
• W4387581629 hasAuthorship W4387581629A5086624112 @default.
• W4387581629 hasAuthorship W4387581629A5088212631 @default.
• W4387581629 hasAuthorship W4387581629A5093052223 @default.
• W4387581629 hasBestOaLocation W43875816291 @default.
• W4387581629 hasConcept C121608353 @default.
• W4387581629 hasConcept C126322002 @default.
• W4387581629 hasConcept C143998085 @default.
• W4387581629 hasConcept C144301174 @default.
• W4387581629 hasConcept C197934379 @default.
• W4387581629 hasConcept C2776256026 @default.
• W4387581629 hasConcept C2777930144 @default.
• W4387581629 hasConcept C2778087573 @default.
• W4387581629 hasConcept C2778375690 @default.
• W4387581629 hasConcept C2779438470 @default.
• W4387581629 hasConcept C2780580887 @default.
• W4387581629 hasConcept C2780586478 @default.
• W4387581629 hasConcept C2908647359 @default.
• W4387581629 hasConcept C38180746 @default.
• W4387581629 hasConcept C71924100 @default.
• W4387581629 hasConcept C99454951 @default.
• W4387581629 hasConceptScore W4387581629C121608353 @default.
• W4387581629 hasConceptScore W4387581629C126322002 @default.
• W4387581629 hasConceptScore W4387581629C143998085 @default.
• W4387581629 hasConceptScore W4387581629C144301174 @default.
• W4387581629 hasConceptScore W4387581629C197934379 @default.
• W4387581629 hasConceptScore W4387581629C2776256026 @default.
• W4387581629 hasConceptScore W4387581629C2777930144 @default.
• W4387581629 hasConceptScore W4387581629C2778087573 @default.
• W4387581629 hasConceptScore W4387581629C2778375690 @default.
• W4387581629 hasConceptScore W4387581629C2779438470 @default.

• next